Letter Re: Safety of Combination Biologic and Antirejection Therapy Post-liver Transplantation in Patients With Inflammatory Bowel Disease

被引：2
作者：
Peverelle, Matthew [1 ]
Mills, Chris [1 ]
Testro, Adam [1 ,2 ]
Gow, Paul [1 ,2 ]
De Cruz, Peter [1 ,2 ]
机构：
[1] Austin Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Med, Austin Acad Ctr, Melbourne, Vic, Australia
来源：
INFLAMMATORY BOWEL DISEASES | 2020年 / 26卷 / 05期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
VEDOLIZUMAB;
D O I：
10.1093/ibd/izaa027
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E35 / E36
页数：2
相关论文
共 5 条
  • [1] Al Draiweesh S, 2019, SAFETY COMBINATION B
  • [2] Early and late onset Clostridium difficile-associated colitis following liver transplantation
    Albright, Jeffrey B.
    Bonatti, Hugo
    Mendez, Julio
    Kramer, David
    Stauffer, John
    Hinder, Ronald
    Michel, Jaime A.
    Dickson, Rolland C.
    Hughes, Chris
    Nguyen, Justin
    Chua, Heidi
    Hellinger, Walter
    [J]. TRANSPLANT INTERNATIONAL, 2007, 20 (10) : 856 - 866
  • [3] Clostridium difficile infection in hospitalized liver transplant patients: A nationwide analysis
    Ali, Muhammad
    Ananthakrishnan, Ashwin N.
    Ahmad, Shahryar
    Kumar, Nilay
    Kumar, Gagan
    Saeian, Kia
    [J]. LIVER TRANSPLANTATION, 2012, 18 (08) : 972 - 978
  • [4] Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting
    Ng, Siew C.
    Hilmi, Ida Normiha
    Blake, Aimee
    Bhayat, Fatima
    Adsul, Shashi
    Khan, Qasim Rana
    Wu, Deng-Chyang
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2431 - 2441
  • [5] Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation
    Wright, Andrew P.
    Fontana, Robert J.
    Stidham, Ryan W.
    [J]. LIVER TRANSPLANTATION, 2017, 23 (07) : 968 - 971
1